IP Library Granted Patent US 11,221,335
Granted Patent B2
US 11,221,335 · App. 16/675,978 · Granted Jan 11, 2022

Heat-treated limulus amebocyte lysates

Inventor: Masakazu Tsuchiya (Mount Pleasant, SC)
Assignee: Charles River Laboratories, Inc.
G01N33/579G01N2400/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,221,335
App. No.
16/675,978
Granted
Jan 11, 2022
Kind
B2
Abstract

The application provides heat-treated Limulus amebocyte lysates useful for detecting β-glucans.

Claims (16)

1. A heat-treated Limulus amebocyte lysate comprising:

i) (1→3)-(β-D-glucan sensitive Limulus Factor G and

ii) Factor C having an endotoxin reactivity less than 0.1% of the endotoxin reactivity of an untreated Limulus amebocyte lysate.

2. The Limulus amebocyte lysate of claim 1 , wherein the Limulus amebocyte lysate is lyophilized.

3. The Limulus amebocyte lysate of claim 1 , wherein the Limulus amebocyte lysate retains sensitivity to 1 pg/mL carboxymethylated pachyman.

4. The Limulus amebocyte lysate of claim 3 , wherein the Limulus amebocyte lysate retains sensitivity to 0.1 pg/mL carboxymethylated pachyman.

5. A Limulus amebocyte lysate according to claim 1 , wherein the lysate is insensitive to 200 EU/mL of Reference Standard Endotoxin.

6. A Limulus amebocyte lysate according to claim 1 , wherein the lysate is insensitive to 0.01 mcg/mL LPS.

7. The Limulus amebocyte lysate of claim 6 , wherein the lysate is insensitive to 0.1 mcg/mL LPS.

8. The Limulus amebocyte lysate of claim 7 , wherein the lysate is insensitive to 1 mcg/mL LPS.

9. The Limulus amebocyte lysate of claim 8 , wherein the lysate is insensitive to 10 mcg/mL LPS.

10. A composition comprising the heat-treated Limulus amebocyte lysate of claim 1 and a substrate.

11. The composition of claim 10 , wherein the substrate is chromogenic.

12. The composition of claim 10 , wherein the substrate is fluorogenic.

13. The composition of claim 10 , wherein the composition is lyophilized.

14. The Limulus amebocyte lysate of claim 1 , wherein the heat-treated Limulus amebocyte lysate comprises inactive Factor C.

Assignments (3)
SECURITY INTEREST Recorded Dec 13, 2024
From: CHARLES RIVER LABORATORIES, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 069647/0925 →
SECURITY INTEREST Recorded Apr 21, 2021
From: CHARLES RIVER LABORATORIES, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 055994/0202 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2020
From: TSUCHIYA, MASAKAZU
To: CHARLES RIVER LABORATORIES, INC.
Reel/Frame 052213/0375 →
Continuity (4)
Division 14228993 · Mar 28, 2014
Division 12823506 · Jun 25, 2010
Provisional Application 61220785 · Jun 26, 2009
Related Publication 20200217845A1 · Jul 9, 2020
Cited By (1)
US 12,540,944